Federal Court Blocks Edwards Lifesciences' Acquisition of JenaValve
A U.S. federal court has blocked Edwards Lifesciences' acquisition of JenaValve Technology, citing reduced competition in the TAVR market. Despite the setback, Edwards raised its 2026 earnings guidance, signaling confidence in its core business.
Insights:
On January 9, 2026, a U.S. federal court ruled against the acquisition of JenaValve Technology by Edwards Lifesciences Corporation , citing concerns over reduced competition in the transcatheter aortic valve replacement (TAVR) market for aortic regurgitation treatment. The decision, made by Judge Rudolph Contreras rudolph contreras, came after the U.S. Federal Trade Commission (FTC) filed a lawsuit in August 2024 to block the deal, arguing that it would decrease competition in this specific market segment.
